IRWD - IRONWOOD PHARMACEUTICALS INC
IEX Last Trade
4.54
-0.060 -1.322%
Share volume: 14,962
Last Updated: Thu 26 Dec 2024 08:30:02 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$4.60
-0.06
-1.30%
Fundamental analysis
63%
Profitability
98%
Dept financing
31%
Liquidity
31%
Performance
44%
Performance
5 Days
0.44%
1 Month
30.97%
3 Months
13.55%
6 Months
-25.40%
1 Year
-59.09%
2 Year
-62.76%
Key data
Stock price
$4.54
DAY RANGE
$4.31 - $4.66
52 WEEK RANGE
$3.43 - $15.70
52 WEEK CHANGE
-$59.81
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Thomas A. McCourt
Region: US
Website: ironwoodpharma.com
Employees: 220
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ironwoodpharma.com
Employees: 220
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation.
Recent news